This trial is studying REGN4018, given alone or together with cemiplimab, to see how well it works in treating patients with solid tumors that have spread (metastatic) or cannot be removed by surgery (unresectable).
7 Primary · 52 Secondary · Reporting Duration: From Cycle 2, Day 1 up to 21 days
Experimental Treatment
554 Total Participants · 2 Treatment Groups
Primary Treatment: REGN4018 · No Placebo Group · Phase 1 & 2
Age 18+ · Female Participants · 8 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: